Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative and neuropsychiatric diseases, announced the completion of a $25m series B equity financing.
Novartis and Blackstone Life Sciences have launched new biopharmaceutical firm, dubbed Anthos Therapeutics, to develop new medicines for cardiovascular disease.
Imbrium Therapeutics, a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, and TetraGenetics, a biotech company developing novel therapeutics for pain indications and autoimmune diseases, announced a strategic research & development collaboration to utilize TetraGenetics’ antibody discovery technology platform (TetraExpress) in the discovery and development of non-opioid biologic therapies for the treatment of chronic pain.
Novartis announced that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy.
Swiss drug maker Roche has agreed to acquire US-based gene therapy company Spark Therapeutics in an all-cash deal worth around $4.3bn.
French pharma company Ipsen has agreed to acquire Canada-based Clementia Pharmaceuticals in an all-cash deal worth up to $1.3bn to boost its rare disease portfolio.
Urovant Sciences, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, announced it has entered into a debt financing agreement with Hercules Capital for up to $100m.
AbbVie and Voyager Therapeutics will engage in the development of vectorized antibodies to treat Parkinson's disease and other synucleinopathies, under a deal worth over $1.5bn.
Morphic Therapeutic, a biotechnology company developing oral integrin therapies, has entered into a research and development collaboration with Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.
Merck has signed an agreement to acquire late-stage immunotherapy firm, Immune Design, in a deal valued at around $300m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.